Brief: Ovid Therapeutics Reports First Quarter 2023 Financial Results And Corporate Updates
05/05/2023 12:32
May 5 (Reuters) - Ovid Therapeutics Inc OVID.O :
* OVID THERAPEUTICS REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS
AND CORPORATE UPDATES
* OVID THERAPEUTICS INC - OV329 PHASE 1 TRIAL CONTINUES TO
PROGRESS ON TRACK WITH NO SAFETY SIGNALS
* OVID THERAPEUTICS INC - INTENDS TO CONCLUDE AND EXPLORE
OUT-LICENSING OF ITS GENETIC MEDICINE PROGRAMS WITH COLUMBIA
UNIVERSITY
* OVID THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.19
Source text for Eikon: ID:nGNX1YthJB
Further company coverage: OVID.O
Recent news on Ovid Therapeutics
See all newsOvid Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Ovid Therapeutics Q2 revenue beats estimates
Brief: Ovid Therapeutics Q2 EPS USD -0.08
Ovid Therapeutics Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Ovid Therapeutics Appoints Leading Physician-Scientist And Biotech Innovator Anna Greka, M.D., Ph.D., To Board Of Directors